Dr Reddy share price target 2014
Dr Reddy share daily chart analysis
Dr Reddy share on last trading session closed at 2552 with 2552 with gain. On daily chart, stock price trend and momentum both are down. Dr Reddy share is trading below major average with bearish divergences on indicators.
From short-term view, below 2630 stock will remains sell and may continue to head down. 2495 and 2360 are support zones as well as target in current scenario. On upside 2630 and 2755 are strong resistances. Traders below 2630 keep sell on rise view for stock future and keep targets on downside. Daily chart indicators and oscillators are bearish and suggesting downtrend may continue ahead.
Dr Reddy share weekly chart analysis
Dr Reddy share on weekly chart closed with loss in this week. Weekly chart price trend is bullish and stock is closed near major average support zone while momentum is bearish as profit booking pressure in increasing in every week. In last 2 months period stock tumbled from 2950 to almost 2500.
From medium term view, traders and investors watch 2500 support and above it keep long view. Below it, 2045 is next support zone on weekly chart. On upside 3065 and 3575 are strong resistances as well as targets for next 6 to 12 months if trend holds. Weekly chart indicators and oscillators patterns are bearish but near oversold zone.
Dr Reddy share monthly chart analysis
Dr Reddy share in last 6 month had given only 4% return to investors and now stock started to underperform. From long-term view 2400 rupees is major level to watch. Above it keep long view and follow buy on dips. 3500 will be target zone for next 12 months while 4440 will be target zone for next 2 to 3 years period. On downside, 1480 was best buy zone, which was last seen in 2011 while 500 rupee was value buy zone, which is last seen in 2009.
Dr Reddy company description
Dr. Reddy’s Laboratories Limited (DRL) is an integrated global pharmaceutical company. The Company operates in three segments: Global Generics segment, which includes its prescription and over-the-counter (OTC) drug products business; Pharmaceutical Services and Active Ingredients (PSAI) segment, which consists of its active pharmaceutical ingredients (API) business and custom pharmaceutical services (CPS) business, and Proprietary Products segment, which consists of DRL’s new chemical entities (NCEs) business, its Differentiated Formulations business and its dermatology focused specialty business operated through Promius Pharma. On March 27, 2012, DRL launched quetiapine fumarate tablets. On March 2, 2012, it launched ziprasidone hydrochloride capsules. On October 24, 2011, DRL launched olanzapine tablets. On July 25, 2011, it launched fondaparinux sodium injection.
Dr Reddy share fundamental ratios
|Range||2,522.55 – 2,570.00|
|52 week||1,859.10 – 2,939.40|